From latent to patent: rethinking prediction of tuberculosis

The Lancet Respiratory Medicine

Volumn 5, Issue 4, 2017, Pages 243-244

  Cobelens, Frank ^a,b   Kik, Sandra ^a,b   Esmail, Hanif ^c,d   Cirillo, Daniela Maria ^e   Lienhardt, Christian ^f   Matteelli, Alberto ^g  

^a AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^b KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

^g UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TRANSMISSION; BACTERIUM IDENTIFICATION; DISEASE ASSOCIATION; HUMAN; INFECTION RISK; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; BLOOD; DISEASE EXACERBATION; ECONOMICS; FORECASTING; INTERFERON GAMMA RELEASE ASSAY; MASS SCREENING; TRANSMISSION;

BIOLOGICAL MARKER; TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; BIOMARKERS; DISEASE PROGRESSION; FORECASTING; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MASS SCREENING; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TUBERCULIN TEST;

EID: 85010700251     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30419-2     Document Type: Note

References (10)

1. 1 Ferebee, SH, Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 26 (1970), 28–106.
2. 2 Stagg, HR, Zenner, D, Harris, RJ, Muñoz, L, Lipman, MC, Abubakar, I, Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med 161 (2014), 419–428.
3. 3 Diel, R, Loddenkemper, R, Nienhaus, A, Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 142 (2012), 63–75.
4. 4 Zak, DE, Penn-Nicholson, A, Scriba, TJ, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 387 (2016), 2312–2322.
5. 5 Esmail, H, Barry, CE, Young, DB, Wilkinson, RJ, The ongoing challenge of latent tuberculosis. Philos Trans R Soc Lond B Biol Sci, 369, 2014, 20130437.
6. 6 Esmail, H, Lai, RP, Lesosky, M, et al. Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission and computed tomography. Nat Med 22 (2016), 1090–1093.
7. 7 Dheda, K, Barry, CE, Maartens, G, Tuberculosis. Lancet 387 (2016), 1211–1226.
8. 8 Wood, R, Middelkoop, K, Myer, L, et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 175 (2007), 87–93.
9. 9 Steinbrück, P, Dănkovã, D, Edwards, LB, Doster, B, Livesay, VT, Tuberculosis risk in persons with ‘fibrotic’ x-ray lesions. Bull Int Union Tuberc 47 (1972), 135–159.
10. 10 Opie, EL, Aronson, JD, Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions. Arch Pathol Lab Med, 4, 1927, 1.